Kailera director granted 38,300 stock options
Kailera Therapeutics director Martin Mackay received a new stock option grant.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kailera Therapeutics director Martin Mackay received a new stock option grant. On April 16, 2026, he was granted options to acquire 38,300 shares of Common Stock at an exercise price of $16.00 per share.
The options were granted as compensation, not through an open‑market purchase or sale, and are held directly. They vest and become exercisable for 100% of the underlying shares on April 16, 2027, subject to his continued service. Following this grant, he holds 38,300 stock options, which expire on April 16, 2036.
Insider Trade Summary
Grant/Award: 38,300 shares
Grant/Award
1 txn
Insider
MACKAY MARTIN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 38,300 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 38,300 contracts (Direct)
Holdings Before and After:
Stock Option (right to buy), 0 to 38,300 contracts (Direct)
Footnotes (1)
- F1. The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Key Figures
Options Granted: 38,300 options
Exercise Price: $16.00 per share
Underlying Shares: 38,300 shares
+3 more
6 metrics
Options Granted
38,300 options
Stock Option grant on April 16, 2026
Exercise Price
$16.00 per share
Stock option strike price
Underlying Shares
38,300 shares
Common Stock underlying the options
Post-Grant Option Holdings
38,300 options
Total derivative securities following transaction
Vesting Date
April 16, 2027
100% of options vest on this date
Expiration Date
April 16, 2036
Option expiration
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "16.0000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-04-16T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Martin Mackay report in this Form 4 for Kailera Therapeutics (KLRA)?
Martin Mackay reported receiving a grant of stock options for 38,300 shares of Kailera Therapeutics Common Stock. These options were awarded as compensation, not bought on the open market, and give him the right to purchase shares at a fixed exercise price of $16.00.
At what price can the new Kailera (KLRA) stock options be exercised?
The new stock options can be exercised at an exercise price of $16.00 per share. This means Mackay can buy Kailera Common Stock at $16.00 once the options vest, regardless of the market price at that time, subject to plan terms.
When do Martin Mackay’s new Kailera (KLRA) options vest and become exercisable?
The options vest and become exercisable as to 100% of the 38,300 underlying shares on April 16, 2027. Vesting is conditioned on Mackay’s continued service with Kailera Therapeutics through that vesting date, according to the filing’s footnote.
How many Kailera (KLRA) derivative securities does Martin Mackay hold after this transaction?
After the reported transaction, Mackay holds 38,300 stock options related to Kailera Common Stock. This equals the full size of the new grant, indicating the Form 4 shows a single award rather than multiple option positions or sales of previously held derivatives.
Is this Kailera (KLRA) Form 4 a stock purchase or sale by Martin Mackay?
The Form 4 shows a grant of stock options, not an open-market stock purchase or sale. Transaction code “A” reflects a grant or award acquisition, so this is compensation-based equity rather than Mackay buying or selling Kailera shares for cash in the market.
When do Martin Mackay’s new Kailera (KLRA) stock options expire?
The stock options expire on April 16, 2036, if not exercised earlier. After that expiration date, the right to purchase the 38,300 shares at the $16.00 exercise price ends, even if the options have vested and were previously exercisable under the award terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
